Chemoradiotherapy improves survival after pancreatic adenocarcinoma resection
the ONA take:
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma, particularly among patients with R1 resection and pN1 disease, according to results from a large national cohort study published online ahead of print in the journal Cancer.
For the study, researchers sought to compare the effectiveness of chemotherapy with chemoradiotherapy in patients with pT1-3N0-1M0 pancreatic adenocarcinoma after pancreatectomy. Researchers identified 6,165 patients from the National Cancer Data Base who were treated with chemotherapy with or without radiotherapy.
Results showed that chemoradiotherapy was associated with improved overall survival vs chemotherapy alone. Subgroup analyses demonstrated that chemoradiotherapy was significantly associated with improved overall survival among those with pT3 or pN1 disease and both R0 resection and R1 resection.
The findings suggest that a prospective randomized head-to-head trial comparing adjuvant chemotherapy with chemoradiotherapy are warranted to assess their efficacy in patients with pancreatic adenocarcinoma who have undergone pancreatectomy.
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|